Proposed treatment guidance on new anticancer agents for the treatment of hepatocellular carcinoma, 2010 up date

  • Kaneko Shuichi
    The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
  • Furuse Junji
    The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
  • Kudo Masatoshi
    The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
  • Ikeda Kenji
    The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
  • Honda Masao
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Nakamoto Yasunari
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Onji Morikazu
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Shiota Goshi
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Yokosuka Osamu
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Sakaida Isao
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Takehara Tetsuo
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Ueno Yoshiyuki
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Hiroishi Kazumasa
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Nishiguchi Shuhei
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Moriwaki Hisataka
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Yamamoto Kazuhide
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Sata Michio
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Obi Shuntaro
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Miyayama Shiro
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
  • Imai Yukinori
    Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma

Bibliographic Information

Other Title
  • 肝がんに対する新規抗がん剤使用に関する指針 2010年度版 平成22年度厚生労働科学研究費補助金(肝炎等克服緊急対策研究事業)
  • カン ガン ニ タイスル シンキ コウガンザイ シヨウ ニ カンスル シシン 2010ネンドバン ヘイセイ 22ネンド コウセイ ロウドウ カガク ケンキュウヒ ホジョキン カンエン トウ コクフク キンキュウ タイサク ケンキュウ ジギョウ

Search this article

Abstract

The Research Team on New Cancer Therapies, funded by a Ministry of Health, Labour and Welfare (MHLW) Grant-in-Aid for Scientific Research (Emergency Research Project to Conquer Hepatitis), summarized the usage performance and side-effect frequency of two drugs in trials conducted on patients with progressive hepatocellular carcinoma at 16 participating facilities until December 22, 2010. The team examined 264 cases in which sorafenib was used, and 535 cases in which miriplatin was used for treatment. To more quickly ascertain views on the current and appropriate use of anticancer agent, and to move toward their use in actual treatment scenarios, the researchers, citing published articles, academic presentations, and reports by companies, presented the problems that arose during treatment as clinical questions, presented recommendations in response to each clinical question regarding the kind of care and treatment that should be given, and compiled guidelines in which their reasons for issuing those recommendations were presented as scientific statements.<br>

Journal

  • Kanzo

    Kanzo 52 (8), 532-551, 2011

    The Japan Society of Hepatology

Citations (2)*help

See more

References(55)*help

See more

Details

Report a problem

Back to top